Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
390 participants
INTERVENTIONAL
2021-01-11
2022-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Non-Ablative Radiofrequency Treatment for Stress Urinary Incontinence
NCT03066180
Comparison of the Viveve Treatment and Cryogen-Only Treatment Versus Sham Treatment for Stress Urinary Incontinence
NCT04206085
Evaluating SUI-100™, A Non-Invasive Device for the Treatment of Stress Urinary Incontinence
NCT06862648
A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI.
NCT05570071
Radiofrequency in the Female Stress Urinary Incontinence
NCT02617797
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Percent of subjects who are responders in the 1-hour Pad Weight Test at 3- and 6-months post-treatment.
* Change from Baseline (CFB) to 3, 6- and 12-months post-treatment in the number of incontinence episodes as assessed by the 3-day bladder voiding diary.
* Percent of subjects with no incontinence episodes at 3, 6- and 12-months post-treatment as assessed by the 3-day bladder voiding diary.
* CFB to 3, 6, 9- and 12-months post-treatment in the I-QOL, ICIQ-UI-SF, PGI-I and MESA questionnaires.
* Percent CFB to 3, 6- and 12-months post-treatment in the 1-hour Pad Weight Test.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sham Comparator
Sham delivers non therapeutic levels of radiofrequency and cryogen
Sham
Sham delivers non therapeutic levels of radiofrequency and cryogen
Active Arm
Active arm delivers radiofrequency and cryogen
Active treatment
Active treatment delivers radiofrequency and cryogen
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active treatment
Active treatment delivers radiofrequency and cryogen
Sham
Sham delivers non therapeutic levels of radiofrequency and cryogen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
I.2 Willing to comply with study requirements and instructions.
I.3 Symptoms and diagnosis of stress urinary incontinence as determined by the following:
1. If there are mixed symptoms there must be a predominant stress component as determined by the 3-day diary results and MESA questionnaire
2. Patient-reported or history of SUI symptoms for \> 6 months prior to screening.
3. Positive Bladder Stress Test at the Baseline Visit.
4. Positive Q-tip test at the Baseline Visit (the observation of an angle that exceeds 30 degrees from horizontal in the opinion of the investigator or designee to denote hypermobility).
5. 1-hour pad weight at the Baseline Visit with a \>10 and \<50 g net increase from the pre-test pad weight.
6. Subjects must complete 3 days in the 3-day voiding diary during 3 consecutive days in the 7 days prior to the Baseline Visit, and subjects must report a minimum of 1 incontinence episode per day or \> 4 incontinence episodes over the 3 days as reported in the 3-day voiding diary.
7. For the Baseline 3-day diary, subjects must be compliant with recording events (i.e. void, leak or fluid intake) as determined through coordinator interview with the subject and review of voids and fluid intake reported in the diary compared to normal daily measurements.
I.4 Pre-menopausal females, ≥18 years of age. Premenopausal is defined as a woman who has had menstrual cycles over the previous 12 months or who is determined to be premenopausal by the PI or sub-investigator (e.g. premenopausal woman with hysterectomy).
I.5 Body mass index (BMI) of ≤35 kg/m² at the Screening Visit. I.6 Normal, or abnormal but not clinically significant (i.e., mild atrophy with rugae present, low grade prolapse), physical, pelvic and neurologic exam at the Baseline Visit as determined by the investigator.
I.7 Negative urine pregnancy test at the Baseline and Randomization Visits and subject agrees to not become pregnant during the study and uses an acceptable form of birth control started at least 3 months prior to screening (with the exception of double barrier contraception, where the 3-months required prior to screening does not apply).
1. Examples of acceptable forms of birth control include: abstinence from heterosexual vaginal intercourse, hysterectomy, bilateral tubal ligation, vasectomy, double barrier contraception (note that condom and spermicide is not considered double barrier contraception), intrauterine device or hormonal contraceptive.
2. Rhythm and withdrawal are not considered acceptable forms of contraception.
Exclusion Criteria
E.2 Undergone other stress urinary incontinence treatment(s), excluding behavioral modifications started \>3 months prior to screening (e.g., Kegel exercises).
E.3 A MESA score of greater than 5 in sum on questions 10 - 12, or greater than 9 in sum on questions 10 - 15 at the screening visit (see appendix).
E.4 A post void residual measurement of greater than 150 ml as measured with ultrasound or bladder scanner at the screening visit.
E.5 Greater than 10 voids per day on average as measured with the 3-day diary at Baseline Visit.
E.6 Greater than 1 nocturia episode per day on average as measured with the 3-day diary at Baseline Visit.
E.7 Abnormal, clinically significant laboratory results at the Baseline Visit (as determined by the Investigator) that could impact the subject participation or evaluation for SUI. Retest is allowed with Sponsor approval.
E.8 Greater than 100 ounces of fluid consumed per day on average as measured with the 3-day diary at baseline Visit.
E.9 History of, or any current condition, illness, or surgery that might confound the results of urinary incontinence assessment, including, but not limited to:
1. Prominent (i.e., greater than Stage II pelvic organ prolapse as determined by a POP-Q evaluation (at Baseline) e.g., cystocele, rectocele
2. Neurological disorders (e.g., multiple sclerosis, Parkinson's disease, fibromyalgia)
3. Recurrent Urinary Tract Infections (UTI)
4. Current Urinary Tract Infection (UTI) as assessed by urine dipstick and associated urinary tract infection symptoms at the Baseline or Randomization Visit. If the subject has a UTI at the Baseline or Randomization Visit they may be treated with antibiotics, at the Investigator's discretion, and return within 7 days after UTI treatment completion.
5. Vesicoureteral reflux
6. Bladder stones
7. Bladder tumors
8. Interstitial cystitis E.10 Has any implantable electrical device \[e.g., implantable pacemaker, automatic implantable cardioverter-defibrillator (AICD)\].
E.11 A rectovaginal septum \<2 cm. E.12 Planning on future pregnancies after the Viveve procedure.
E.13 Medical or immunological condition, including, but not limited to:
1. Uncontrolled cardiovascular, respiratory, neoplastic, infectious, and/or endocrinological condition that could impact the subject's ability to complete the trial.
2. Uncontrolled diabetes defined as hemoglobin A1c \> 7%
3. Untreated chronic abdominal/pelvic pain disorder \[including, but not limited to, dyspareunia, vaginismus, endometriosis, significant vulvovaginal atrophy (VVA), genitourinary syndrome of menopause (GSM), irritable bowel syndrome, or Crohn's disease\].
4. Untreated medical condition or medication that, in investigator's opinion, may interfere with adequate wound healing response (e.g., congenital connective tissue disease) or the subject's ability to complete the clinical trial requirements.
5. Untreated active malignancy (with the exception of basal cell carcinoma of the skin) or undergoing treatment (using chemotherapeutic agents, radiation therapy, and/or cytostatic medications) that may interfere with adequate wound healing response or the subject's ability to complete the trial.
6. Untreated acute or chronic vaginal or vulvar disorder including, but not limited to, vulvovaginal atrophy/GSM; pain, including provoked/generalized vulvodynia, vulvar vestibulitis, dysesthetic vulvodynia, or vulvar dystrophy; current/chronic papulosquamous vulvar dermatoses (e.g., psoriasis, lichen planus, tinea cruris, lichen sclerosis, seborrheic dermatitis, contact/irritant dermatitis, lichen simplex, eczema); bullous dermatoses; systemic diseases with potential involvement of vulva; genital warts; past/current vaginal or vulvar radiotherapy or brachytherapy.
7. Active genital/pelvic infection (e.g., herpes, gonorrhea, chlamydia) observed on physical or pelvic exam at Baseline.
8. Active yeast infection. If the subject has an active vaginal yeast infection at the Baseline or Randomization Visit, they may be treated with an antifungal, at the Investigator's discretion, and return within 7 days after completion of vaginal yeast infection treatment.
E.14 Chronic use of anti-inflammatory drugs, including ibuprofen, aspirin, and oral steroids (excluding aspirin that is taken for cardiovascular prophylaxis).
E.15 Started taking any new medication, including herbal supplements and those taken in teas that potentially affects urination within 28 days prior to the Screening Visit, or had a change in the dosage of any medication that potentially affects urination within 28 days of the Screening Visit. Dosage should not change for the remainder of the study unless medically necessary.
E.16 Started or changed dose of local vaginal hormones \<6 weeks before screening.
E.17 Undergone previous elective surgical or non-invasive procedure(s) in the vaginal canal (including previous treatment with the Viveve System or any other genital radiofrequency treatment; injectable bulking agent, cosmetic, laser, surgical, and/or genital enhancement procedure).
E.18 Participated in another clinical study within 6 months of screening or is not willing to abstain from participating in other clinical studies for duration of trial.
E.19 Employed by Viveve or participating investigative sites.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Viveve Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric S Rovner, MD
Role: PRINCIPAL_INVESTIGATOR
Medical University of South Carolina
Roger R Dmochowski, MD
Role: STUDY_DIRECTOR
Vanderbilt University Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Coastal Clinical Research
Mobile, Alabama, United States
Urological Associates of Southern Arizona, PC
Tucson, Arizona, United States
Long Beach Clinical Trials Services, Inc.
Long Beach, California, United States
Emerson Clinical Research Institute
Washington D.C., District of Columbia, United States
IntimMedicine Specialists
Washington D.C., District of Columbia, United States
Multi-Specialty Research Associates, Inc
Lake City, Florida, United States
A Premier Medical Research of Florida
Orange City, Florida, United States
Florida Urology Partners
Tampa, Florida, United States
Leavitt Clinical Research
Idaho Falls, Idaho, United States
Cypress Medical Research Center, LLC
Wichita, Kansas, United States
Research Integrity, LLC
Owensboro, Kentucky, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
Chesapeake Urology Research Associates
Owings Mills, Maryland, United States
Minnesota Women's Care, P.A.
Maplewood, Minnesota, United States
Boeson Research
Missoula, Montana, United States
Adult and Pediatric Urology
Omaha, Nebraska, United States
AccuMed Research Associates
Garden City, New York, United States
Circuit Clinical
West Seneca, New York, United States
Unified Women's Health Care of Raleigh
Raleigh, North Carolina, United States
UWCR-Lyndhurst Clinical Research
Winston-Salem, North Carolina, United States
Clinical Research Solutions
Middleburg Heights, Ohio, United States
The Clinical Trial Center, LLC
Jenkintown, Pennsylvania, United States
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Venus Gynecology, LLC
Myrtle Beach, South Carolina, United States
Advances In Health Research
Houston, Texas, United States
Cedar Health Research
Irving, Texas, United States
Maximos OB/GYN
League City, Texas, United States
Urology San Antonio
San Antonio, Texas, United States
Health Research of Hampton Roads, Inc
Newport News, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VI-17-06
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.